Frontotemporal disorders treatment market

Increasing Funding by Government & Non-Government Organizations

The global frontotemporal disorders treatment market has been witnessing large number of research activities, associated with drug development for prevention and cure of FTD. Research activities are shifting from clinical research centers and academic laboratories to pharmaceutical companies, with increasing demand and market potential globally. Several major companies are focusing towards development of medications for treatment of FTD. These companies have considerable pipeline drugs dedicated for the treatment. Also, there are several research programs led by government and non-profit organizations, that are dedicated for the promotion of FTD treatment. For instance, the Alzheimer's Drug Discovery Foundation (ADDF) and the Association for Frontotemporal Degeneration (AFTD) launched the Treat FTD Fund. It is stimulating the development of new FTD therapies by funding for the early-stage clinical trials. The program includes an award up to USD 2 million for supporting the testing of drugs and devices for FTD treatment

Most of these development activities are directed towards the development of disease-modifying drugs by understanding the pathogenic mechanisms underlying FTD.

Covid-19 Impact analysis

As the coronavirus disease 2019 (COVID-19) pandemic spreads, it will continue to affect the pharmaceutical industry. Frontotemporal disorders treatment is no exception, and the effect on its drug market will be multifaceted

Inaccessibility of healthcare providers (HCPs) and other medical decision-makers led to a decline in FTD treatment procedures. During the spread of the novel coronavirus and social restrictions imposed thereof, patients diagnosed with early stage of FTD have delayed treatment procedures. This will slow down medication uptake across the world. Also, manufacturers that are preparing to launch new drugs during the lockdown period or the next may decide to postpone marketing or do a soft launch, which would entail supplying the product. This could affect the global FTD drugs market during the COVID-19 period. Also, the market has been affected from the supply side owing to disruptions in production of drugs. Freight challenges and trade restrictions led to uneven supply of APIs, particularly from China. China and India are accounting for nearly 80% of the API demand in the U.S.. Thus, these supply chain disruptions is likely to affect pharmaceutical manufacturing in many countries such as the U.S. and Europe. The annual growth of the global FTD drugs market is likely to be recorded as XX% in 2020, down from that of XX% in 2019. However, the lowering number of new COVID-19 cases and ease of lockdown restrictions is leading to market recovery at a faster pace, particularly in Asia Pacific region. Also, individuals infected with the novel coronavirus are exhibiting neurological symptoms. Studies conducted on severe COVID-19 patients have reported that 84% of surveyed population experienced rapid mood changes and mental confusion post-recovery.  The studies also estimated long-term consequences on the brain. These factors are likely to pose a positive impact on the demand for antidepressants and antipsychotics in over the forecast period

Frontotemporal Disorders Treatment Market Segmented by drug class are cognitive enhancers, Antidepressants, Antipsychotics, CNS stimulants and Others.

Cognitive Enhancers

The cognitive enhancers market for frontotemporal disorders treatment is likely to reach USD XX million in 2027, from its recorded value of USD XX million in 2019, growing at a CAGR of 6.9% during the forecast period. 

Cognitive enhancers, also known as ‘smart drugs’ or ‘brain doping’, are used to enhance cognitive functions including short-term memory, concentration, comprehension and alertness. With the growth of research in the area of cognitive enhancers, the importance of executive function and inhibitory cognitive control in addictive disorders is becoming increasingly apparent. An emerging case of frontotemporal disorders involves the use of cognitive enhancers as it the cognitive function of the patients. In particular, agents that facilitate inhibitory and attentional control, improve abstraction, planning and mental flexibility could be beneficial in the treatment of substance use disorders.  Because there are multiple neurotransmitter systems involved in the regulation of cognitive function, agents from a number of drug classes have been tested. People can live with frontotemporal disorders for up to 10 years, sometimes longer, but it is difficult to predict the time course for an individual patient. The disorders are progressive, meaning symptoms get worse over time. No cure or treatments that slow or stop the progression of frontotemporal disorders are available today. However, cognitive enhancers can improve blood flow to the brain, reduces brain inflammation, and contains potent antioxidants which protect vulnerable brain cells from free radical damage. However, these drugs tend to affect each user differently, so there is no guarantee that a nootropic will work for a particular patient in frontotemporal disorders the way he needs it to. This is why many people tend to experiment with nootropic use in the beginning, in order to find a product that works the best with their own unique brain chemistry. This factor will hinder the market growth in the forecast period. Cognitive enhancers are relatively safe to use. However, just like any other substance or medication that intake to the body has to use these enhancers safely. This means using the appropriate dosages, paying attention to signs that does or doesn’t body tolerate the use of an enhancer, and preferably consulting a professional before starting use. The US and New Zealand are the only two countries where direct-to-consumer advertising of prescription drugs is legal. This scenario is quite different from India and other parts of the world where such advertising is not allowed, and, where one would assume, public awareness about cognitive enhancement drugs would be lower. However, the prevalence of frontotemporal disorders is increasing in the U.S, which will further drive the market growth of cognitive enhancers.

About Us:

DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year we have secured more than 100 unique customers from established organizations all over the world.

For more information:

Sai Kiran

Sales Manager at DataM Intelligence

Email: [email protected]

Tel: +1 877 441 4866

Website: www.datamintelligence.com